

1 Trends in Diabetes Biomarkers and
2 Treatment Statuses of Non-
3 Institutionalized Canadians: Canadian
4 Health Measures Survey 2007 to 2015

5 **Authors**

6 1. Yi-Sheng Chao, MD MPH PhD*

7 Independent researcher

8 Email: chaoyisheng@post.harvard.edu

9 *Corresponding author

10

11

12 Abstract

13 Background

14 Diabetes has been a major source of disease burden in Canada. Moreover, untreated
15 diabetes can lead to complications and severe conditions. A few studies exist on the prevalence
16 of diabetes and the adequacy of diabetes management for the Canadian population, and so this
17 study aims to estimate the diabetes prevalence rates using biomarkers and the treatment
18 statuses of non-institutionalized Canadian patients.

19 Methods

20 The Canadian Health Measures Survey (CHMS) cycles 1 to 4 were conducted between
21 2007 and 2015 as interviews with non-institutionalized Canadians. Four blood diabetic markers
22 were measured: insulin, glycosylated hemoglobin percentages, random-spot glucose, and
23 fasting glucose. Subjects with levels higher than normal ranges were considered to have pre-
24 diabetes or diabetes. Treatment statuses were categorized into *treated* (using anti-diabetic
25 agents or diagnosed with diabetes), *probably treated* (taking prescriptions or diagnosed with
26 chronic conditions), *potentially treated* (taking any medications or diagnosed with chronic
27 conditions), and *untreated* (not taking any medications and not diagnosed with chronic
28 conditions). Weights were applied to generate nationally representative statistics.

30 Results

31 The blood insulin levels in cycle 4 were significantly higher than those in cycle 1 (ratio =
32 1.42, 95% CI = 1.04 to 1.79). The proportions of patients with pre-diabetes and diabetes were
33 estimated differently at 0.75% using random-spot glucose and 42.17% using glycosylated
34 hemoglobin percentages, respectively. The proportions of Canadians with uncontrolled pre-
35 diabetes or diabetes varied from 0.59% using random-spot glucose levels to 4.63% using fasting
36 glucose levels, respectively. Through cycles 1 to 4, the proportions of untreated Canadians with
37 pre-diabetes or diabetes ranged from 3.86% to 3.73%. More than 93% of those with high
38 fasting glucose levels were taking prescription medications or had been diagnosed with chronic
39 conditions (probably treated). Less than 33% of those with high fasting glucose levels were
40 diagnosed or actively being treated with anti-diabetic agents (treated).

41 Conclusion

42 Diabetes biomarkers might be useful for screening untreated and undertreated patients
43 with pre-diabetes or diabetes. The treatment categories we used indicated different intensities
44 of intervention that might be useful for determining levels of patient outreach and for planning
45 targeted screening in Canada.

46 Key words

47 Diabetes; pre-diabetes; Canadian Health Measures Survey; biomarker; insulin

48

49 Introduction

50 In 2017 in Canada, diabetes was the seventh leading cause of death and the third cause
51 of disability.[1] Diabetes Canada predicted more than 5 million or 12.1% of the Canadian
52 population will be diabetic by 2025.[2] In the United States in 2011 and 2012, diabetes was
53 estimated to be prevalent in 12.5% of the American population, and 30% of those with diabetes
54 had not been treated.[3] In Canada, between 2007 and 2011, estimates predicted that 7.55% of
55 Canadian adults were diabetic based on levels of fasting glucose and hemoglobin A1c, and
56 43.67% of these adults had not been diagnosed.[4] Diabetes is a chronic condition caused by
57 several mechanisms. Type 1 diabetes involves destroyed pancreatic beta cells and insulin
58 deficiency.[5] Type 2 diabetes development is related to genetic predisposition and molecular
59 mechanisms that subsequently lead to impaired beta cells' glucose responsiveness, insulin
60 resistance, and increases in blood glucose levels.[6, 7] Type 1 diabetes is less frequent[7] and
61 usually occurs at a young age and requires insulin for treatment.[8, 9] Type 2 diabetes develops
62 gradually and is associated with several risk factors, such as being overweight, high blood
63 pressure, and a family history of diabetes.[7] If left untreated and uncontrolled, the long-term
64 complications can include vision loss, cardiovascular disease, and diabetic neuropathy with
65 nerve damage.[7]

66 Within communities, the detection and treatment of patients with diabetes is
67 challenging. Different diabetes biomarkers, such as fasting and random-spot glucose levels, can
68 yield various estimates of diabetes prevalence. For example, the levels of hemoglobin A1c seem
69 to detect more patients with diabetes, compared to the levels of fasting plasma glucose.[4]
70 Often, after estimating the prevalence of diabetes, some studies do not report on the
71 treatment status of diabetic patients.[4] In other studies, a significant treatment gap exists
72 regarding cardiovascular disease management for diabetic patients.[10] Among patients with
73 hypertension, 14.4% of it was uncontrolled.[11] It remains unclear whether higher proportions
74 of patients with diabetes are treated. Whereas a timely diagnosis and effective treatment are
75 keys to reducing diabetic complications at the individual level,[7] at a population level, it is
76 important to know the numbers of patients with diabetes who are undiagnosed or
77 undertreated. However, continued efforts to identify proportions of undiagnosed or untreated
78 patients with diabetes have been lacking.[4] Since recent trends in diabetes biomarkers have
79 not been reported in Canada, our study fills this gap by providing the trends of diabetes
80 biomarkers and the treatment status of Canadian patients with abnormal diabetes biomarker
81 profiles.

82 Methods

83 Our study uses the data from the biannual Canadian Health Measures Survey (CHMS),
84 cycles 1 to 4 implemented between 2007 and 2015.[12, 13] More than 5,000 non-
85 institutionalized Canadians were sampled for each cycle to derive nationally representative
86 statistics.[12, 13] Institutionalized Canadians and those living on reserves, who constituted less
87 than 4% of Canadians, were excluded from the sampling.[13] Detailed inclusion and exclusion
88 criteria and sampling frames were published elsewhere.[13-16] Participants in the CHMS were
89 interviewed regarding their health conditions and individual characteristics.[13, 17] Mobile
90 units collected blood and urine samples to determine levels of disease biomarkers and

91 environmental chemicals.[18] An exclusive list of biomarkers was published in the CHMS
92 Content Summary.[19]

93 **Abnormality identification for blood diabetic biomarkers**

94 Since the CHMS screened for levels of biomarkers with a single measurement, it could
95 not replicate the procedures for diagnosing diabetes used in clinical settings, particularly the
96 use of repeated tests and higher thresholds according to the Diabetes Canada diagnosis
97 guidelines.[20] The present study used clinical reference ranges to estimate the proportions of
98 Canadians with levels of biomarkers higher or lower than the higher and lower limits of clinical
99 reference ranges, respectively. The normal ranges for fasting glucose levels were between 3.9
100 and 6.1 mmol/L or 70 and 110 mg/dL.[21] The upper limit of random glucose levels was 11.1
101 mmol/L or 200 mg/dL.[22] The range of insulin levels was between 14.35 and 143.5 pmol/L or 2
102 and 20 μ U/mL.[22] The normal range for glycosylated hemoglobin percentages was between
103 4% and 5.6%.[22]

104 The CMHS cycles 1 to 4 measured blood insulin levels and glycosylated hemoglobin
105 percentages. Levels of random-spot glucose were measured in cycle 1 and 2, and levels of
106 fasting glucose were measured in cycle 3 and 4.

107 In the CMHS, the diabetes biomarker measurements used had upper and lower
108 detection limits, so the levels of biomarkers that were higher or lower than these limits could
109 not be quantified. The proportions of Canadian participants with levels lower than the
110 detection levels of insulin were 8.08% and 0.07% in cycle 1 and 2, respectively. There were no
111 participants who had levels of other diabetic measures that were higher or lower than the
112 respective upper and lower detection limits.

113 **Treatment status identification**

114 *Treatment status* was defined according to the use of medication and the chronic
115 condition diagnoses. This status was estimated by four categories: *treated*, *probably treated*,
116 *potentially treated*, and *untreated*. To avoid over-identification, *untreated individuals* were
117 defined as those who participants had not reported any chronic conditions or used the
118 medications listed in Appendix 1. Individuals were regarded as *treated* only if they had been
119 diagnosed with diabetes or were taking diabetic prescription drugs listed in Appendix 1. Some
120 patients diagnosed with diabetes might receive a non-medicinal treatment, such as life-style
121 interventions only.[23]

122 Individuals were *probably treated* if they were diagnosed with chronic conditions
123 defined by the CHMS (any chronic conditions such as cardiovascular disease, high blood
124 pressure, abnormal lipid profile, stroke, kidney disease, liver disease, thyroid disease, diabetes,
125 cancer, eating disorder, and chronic obstructive pulmonary disease listed in Appendix 1) that
126 might affect clinical biomarkers or were taking any prescription drug. Individuals were regarded
127 as *potentially treated* if they were diagnosed with the above-mentioned conditions or were
128 taking any prescription or over-the-counter drug. The difference between *probably* and
129 *potentially treated* statuses was the use of over-the-counter medications.

130 *Chronic conditions* were identified using the CHMS data dictionaries and were variables
131 beginning with “ccc.”[24] *Medication use* was based on the Anatomical Therapeutic Chemical
132 (ATC) classification system.[25] Medication listed in the CHMS data was labelled as prescription,

133 over-the-counter drugs, and health products. Over-the-counter drugs and health products were
134 regarded as non-prescription. Treatment status identification using disease reporting and
135 medication has been tried in several studies,[11, 26-28] but the present study adopted multiple
136 categories to demonstrate the uncertainties in determining treatment status.

137 Data analysis

138 The present study used all the CHMS cycles 1 to 4 variables to conduct its trend analysis.
139 [14, 15, 29] First, it summarized all the CHMS variables according to their basic characteristics,
140 such as their maximal and minimal values.[14, 15] Then we matched the survey and bootstrap
141 weights to the variables.[14, 15] Next, we processed the variables to identify missing values and
142 values beyond the detection levels. We also documented the basic characteristics, such as
143 weighted mean, and 25th and 75th percentiles.[14, 15] We conducted the data analysis using R
144 (v3.20)[30] and RStudio (v0.98.113)[31]. Due to the descriptive purpose of the present study,
145 we reported 95% CIs, rather than p values. To protect participant confidentiality and prevent
146 any participants from being identified, Statistics Canada has multiple rules on the types of
147 statistics that can be published. For example, minimal numbers of unweighted sample sizes are
148 required for individual categories.

149 Results

150 The CHMS cycles 1 to 4 estimated that there were 29.2 to 32.3 million non-
151 institutionalized Canadians with diabetes, 50% of whom were female.[14, 15] Through cycles 1
152 to 4, the mean age was around 39 years.[14, 15] Through these four cycles, the mean BMI
153 remained similar, from 26.0 to 26.2 kg/m². [14, 15]

154 Trends in diabetic markers

155 The blood insulin levels in cycle 4 were significantly higher than those in cycle 1 (ratio =
156 1.42, 95% CI = 1.04 to 1.79; mean = 67.78 and 89.87 in cycle 1 and 4, Table 1). The glycosylated
157 hemoglobin percentages in cycle 2 to 4 were not significantly different from the values in cycle
158 1 in Table 2 (ratio 95% CIs including 1 in cycle 2 to 4, weighted means = 5.58%, 5.69%, 5.41%,
159 and 5.42% in cycle 1 to 4, respectively). Levels of random-spot glucose (mmol/l) were measured
160 in cycle 1 and 2, and the levels in cycle 2 were not significantly different from those in cycle 1 in
161 Table 3 (ratio = 1.09, 95% CI = 0.90 to 1.27, weighted means = 4.96 and 5.08 in cycle 1 and 2,
162 respectively). We measured the levels of fasting glucose in cycles 3 and 4, and the levels in cycle
163 4 were not significantly different from those in cycle 3 (ratio = 1.03, 95% CI = 0.91 to 1.16,
164 weighted mean = 5.17 and 5.20 in cycle 3 and 4, respectively) (Table 4).

165 Proportions with levels higher or lower than reference levels

166 The proportions of the population with levels higher or lower than the clinical reference
167 ranges varied across the CHMS cycles and diabetes biomarkers. The proportions with insulin
168 levels higher than the reference ranges were 7.52%, 6.81%, 8.42%, and 11.5% in the CHMS
169 cycles 1 to 4, respectively (Table 1). Only 4.49% of Canadians were found to have insulin levels
170 lower than the clinical reference ranges in cycle 1. The unweighted sample sizes in cycles 2 to 4
171 were not large enough for Statistics Canada to release weighted statistics. The proportions of
172 the population with high glycosylated hemoglobin were 34.12%, 42.17%, 15.88%, and 18.83% in

173 cycles 1 to 4, respectively (Table 2). The proportions with high random-spot glucose levels were
174 0.75% and 0.84% in cycles 1 and 2, respectively (Table 3). The proportions with high fasting
175 glucose levels were 14.42% and 14.38% in cycles 3 and 4, respectively (Table 4).

176 The lower limits of the reference ranges for random-spot glucose levels were not
177 defined and not available (Table 3). No subjects were identified with low glycosylated
178 hemoglobin percentages in cycles 1 to 4 (Table 2). The proportions with low fasting glucose
179 levels were 1.92% and 0.53% in cycles 3 and 4, respectively (Table 4).

180 **Treatment status**

181 Based on Statistics Canada's regulations, no sufficient unweighted sample sizes were
182 available to determine the proportions of various treatment statuses for high insulin and low
183 fasting glucose levels. There were no subjects with low glycosylated hemoglobin percentages.

184 In cycle 1, among those with low insulin levels, 3.15%, 88.87%, and 96.85% were
185 untreated, probably treated, and potentially treated, respectively (Table 1). However, no
186 sufficient unweighted subjects were available to determine the proportions of those treated.
187 Among those with high levels of glycosylated hemoglobin percentages, the proportions of those
188 who were untreated were 3.86%, 3.75%, 1.78%, and 3.73% in cycles 1 to 4, respectively. The
189 proportions of those treated ranged from 11.38% to 29.91% across cycles 1 to 4. The
190 proportions of those probably treated ranged from 87.21% to 93.22% across cycles 1 to 4.
191 Among those with high insulin levels who were potentially treated, the range was 96.14% to
192 98.22%.

193 Among those with high random-spot glucose levels, no untreated subjects were
194 identified, and the proportion of those who were probably or potentially treated was 100%
195 across cycles 1 to 2. The proportions of those treated were 78.84% and 93.02% in cycles 1 and 2,
196 respectively. Among those with high fasting glucose levels, the proportions of those who were
197 untreated were 0.46% and 0.72% in cycles 1 and 2, respectively. The proportions of those
198 being treated were 27.0% and 32.2% in cycles 1 and 2, respectively. The proportions of those
199 being probably or potentially treated were more than 93.37% in cycles 1 and 2. Among those
200 with low fasting glucose levels, 5.23% and 3.26% were untreated in cycles 3 and 4, respectively.
201 The proportions of those being probably treated were 59.84% and 72.36% in cycles 3 and 4,
202 respectively. The proportions of those being potentially treated were 94.77% and 96.74% in
203 cycles 3 and 4, respectively.

204

205 **Overall proportions of patients with pre-diabetes or diabetes identified**

206 Among all non-institutionalized Canadians, the proportions of untreated patients with
207 diabetes and pre-diabetes identified by the biomarkers varied. Insulin levels failed to identify
208 enough diabetic patients for Statistics Canada to release the estimates. Glycosylated
209 hemoglobin percentages identified 3.86% to 3.73% of untreated Canadians with diabetes or
210 pre-diabetes throughout cycles 1 to 4. Random-spot glucose levels failed to identify any
211 untreated diabetic patients. Fasting glucose levels identified 0.07% and 0.1% of Canadians with
212 diabetes and those who were untreated for diabetes, respectively.

213 In contrast, the proportions of patients with diabetes being treated also varied. Since
214 these patients were treated and their biomarker levels remained high, they could be
215 considered patients with uncontrolled or poorly controlled diabetes. Glycosylated hemoglobin

216 percentages identified 3.88% to 4.78% of Canadians with uncontrolled pre-diabetes or diabetes
217 through cycles 1 to 4. Random-spot glucose levels identified 0.59% to 0.84% of Canadians with
218 uncontrolled pre-diabetes or diabetes in cycles 1 and 2, respectively. Fasting glucose levels
219 identified 3.89% and 4.63% of Canadians with uncontrolled pre-diabetes or diabetes in cycles 3
220 and 4, respectively.

221 Discussion

222 Through cycles 1 to 4, blood insulin levels among non-institutionalized Canadians
223 increased significantly. The proportions of Canadians with high or low levels of diabetes
224 biomarkers varied across the CHMS cycles and the types of diabetes biomarkers. The
225 proportions of treatment also varied depending on the biomarkers and treatment indicators.
226 Previous research on the treatment status of patients with diabetes is scarce and is not
227 representative of the Canadian population.[32] Thus, the trend analysis of diabetes markers is
228 feasible and has important implications for the detection of patients with diabetes in
229 populations. First, across the four CHMS cycles conducted between 2007 and 2015, except for
230 blood insulin levels, the levels of diabetes biomarkers, blood glycosylated hemoglobin
231 percentages, random-spot glucose, and fasting glucose did not change significantly, compared
232 to the levels first measured among non-institutionalized Canadians.[14, 15] However, the lack
233 of significant changes over time should be further examined with other statistics. For example,
234 the proportions of non-institutionalized Canadians taking anti-diabetic agents increased from
235 3.45% to 4.07% from cycles 1 to 4.[15] The proportions of being diagnosed with diabetes also
236 increased from 3.97% to 5.27% from cycles 1 to 4.[15] Whether this finding will be identified in
237 the next CHMS cycles needs to be confirmed.

238 Second, the proportions of patients with pre-diabetes or diabetes identified by diabetes
239 biomarkers vary widely, from less than 1% by random-spot glucose levels to more than 40% by
240 glycosylated hemoglobin percentages. The upper limits of random-spot glucose are set to a
241 high level at ≥ 11.1 mmol/L or ≥ 200 mg/dL that is applicable to patients with symptoms of
242 hyperglycemia.[22] Without information on the symptoms of hyperglycemia, an application of
243 this standard detects small proportions of diabetic patients in the population at 0.75% and
244 0.84% in cycles 1 and 2, respectively. In contrast, using glycosylated hemoglobin percentages,
245 the proportions of patients with pre-diabetes or diabetes are estimated to be as high as 42.17%.
246 In contrast, based on biomarkers, diabetes prevalence in the general population in the United
247 States was estimated to be 6.5%.[33] It is unclear whether using 5.6% glycosylated hemoglobin
248 to screen for patients with pre-diabetes and diabetes may result in over-identification. Diabetes
249 identification using this biomarker in the general population needs further research.

250 Third, four categories of treatment statuses can be used to guide the efforts to identify
251 untreated or undertreated patients. Being identified as *probably* or *potentially* treated suggests
252 different levels of exposure to health care systems. The diagnosis of chronic conditions
253 documented in the CHMS has been used to assign a *probably treated* status. A current use of
254 prescription or over-the-counter medications can lead to the identification of a *potentially*
255 *treated* status. Based on such information, more than 93% of those with high fasting glucose
256 levels were taking prescription medications or had been diagnosed with chronic conditions,
257 whereas less than 33% of them were actively treated with anti-diabetic agents. This suggests

258 that about 60% of those with high fasting glucose levels could be identified and treated
259 medically, if they were not experiencing life-style management for diabetes or undergoing
260 treatment for other conditions. Those with a *potentially treated* status without definite
261 diabetes treatment could have been detected if screening was available where they obtained
262 medications. The proportions of these treatment statuses can guide health care decision
263 makers as to how and where to approach untreated patients with diabetes.

264 Last, we need to focus on the patients with diabetes, who do not have a clear indication
265 for receiving medical treatment. Using glycosylated hemoglobin percentages or fasting glucose
266 levels, the proportions of untreated Canadians with pre-diabetes or diabetes ranged between
267 0.7% and 1.58% or 0.07% and 0.1%, respectively. These estimates were lower than those
268 reported in the US[3] or the rates between 2007 and 2011 in Canada.[4] To what extent the
269 differences can be attributed to prevalence or methodological differences remains unclear.
270 However, despite these differences, important economic and health consequences exist for
271 individuals and the public with respect to delaying diabetes treatment.[34] If biomarker
272 screening is considered for untreated diabetes, more precise estimates of the numbers of
273 affected patients and the associated costs and barriers to screening will be major issues. Future
274 releases of CHMS data may help to provide more accurate estimates.

275 Diabetes screening may be in a greater need during and after the coronavirus disease
276 2019 (COVID-19) pandemic that has reduced individual contact and the exposure to health care
277 systems.[35] Co-morbidity, especially diabetes, is associated with severe COVID-19 symptoms
278 and more deaths.[36] Early detection of diabetes with biomarkers can help to prevent disease
279 progression and complications.[37] Thus, the detection of diabetes will play a more important
280 role in health care in Canada and elsewhere.

281 Limitations

282 This analysis has several limitations despite the use of national representative data,
283 multiple cross-sectional data, and decreasing proportions of subjects with levels lower than the
284 detection limits over time. The CHMS is a biomonitoring study that aimed to provide descriptive
285 statistics but had no power analysis for any specific hypotheses. To be consistent with a
286 previous study, reference ranges were chosen as such.[4] Other reference ranges adopted by
287 professional societies might lead to some differences in the proportions of patients with
288 diabetes.[20] The CHMS surveyed non-institutionalized Canadians[13-15], and its results were
289 not likely to be applicable to those institutionalized. Moreover, the biomarker levels were not
290 adjusted for the effects of glucose-lowering agents. In addition, the biomarker levels were not
291 adjusted for population structures. Regarding the glycosylated hemoglobin percentages, the
292 diagnosis of pre-diabetes was not separated from diabetes. The measures to prevent the
293 spread of COVID-19 also denied our access to the CHMS, so we were unable to retrieve further
294 research on details, such as the proportions of diabetes based on the glycosylated hemoglobin
295 percentages.

296 Conclusion

297 The levels of three diabetes biomarkers—glycosylated hemoglobin percentages,
298 random-spot glucose, and fasting glucose—for non-institutionalized Canadians remained stable
299 between 2007 and 2015. Insulin levels were significantly higher in cycle 4 than in cycle 1. The

300 proportions of patients with pre-diabetes or diabetes were estimated differently, from 0.75%
301 using random-spot glucose to 42.17% using glycosylated hemoglobin percentages. The use of
302 anti-diabetic agents was used to identify treated patients with diabetes, and the proportions
303 varied from 0.59% using random-spot glucose levels to 4.63% using fasting glucose levels. The
304 use of prescription medications and the diagnoses of the chronic conditions documented in the
305 CHMS were used to identify those who might be probably treated for pre-diabetes or diabetes.
306 The proportions of probable treatment ranged from 0.75% using random-spot glucose levels to
307 36.78% using glycosylated hemoglobin percentages. Those without chronic conditions or
308 medication use were considered untreated. The proportions of untreated patients with
309 diabetes ranged from 0% using random-spot glucose levels to 1.58% using glycosylated
310 hemoglobin percentages. The use of diabetes biomarkers to screen for patients with pre-
311 diabetes or diabetes might yield unexpected results, and so this screening needs to be planned
312 well. For example, random-spot glucose levels might not be useful for identifying patients with
313 diabetes, and glycosylated hemoglobin percentages might identify high proportions of patients
314 with diabetes in the population. In addition, the treatment categories used in the present study
315 might be useful for planning targeted screening in different contexts.

316 Declaration

317 Acknowledgement

318 The analysis presented in the present study was conducted at the Quebec
319 Interuniversity Centre for Social Statistics (QICSS), which is part of the Canadian Research Data
320 Centre Network (CRDCN). The services and activities provided by the QICSS are made possible
321 by the financial or in-kind support of the Social Sciences and Humanities Research Council
322 (SSHRC), the Canadian Institutes of Health Research (CIHR), the Canada Foundation for
323 Innovation (CFI), Statistics Canada, the Fonds de recherche du Québec and the Quebec
324 universities. The views expressed in this paper are those of the authors, and are not necessarily
325 those of the CRDCN or its partners. The authors thank Dr To-Pang Chen for his constructive
326 comments.

327 Ethics approval

328 This secondary data analysis was approved by the ethics review committee at the
329 Centre Hospitalier de l'Université de Montréal. All methods were performed in accordance with
330 the guidelines and regulations relevant to the analysis of public data.

331 Consent to participate

332 Written informed consent for the Canadian Health Measures Survey was obtained by
333 Statistics Canada and is not accessible to researchers. Due to this restriction, the requirement
334 of written informed consent was waived by the ethics review committee at the Centre
335 Hospitalier de l'Université de Montréal.

336 Acknowledgements

337 Not applicable.

338 **Funding**

339 No specific funding was received for this study.

340 **Financial Disclosure**

341 No funding bodies had any role in the study design, data collection and analysis,
342 decision to publish, or preparation of the manuscript

343 **Competing interests**

344 YSC is currently employed by the Canadian Agency for Drugs and Technologies in Health.
345 The other authors declare that they have no competing interests.

346 **Author contribution**

347 YSC conceptualized and designed this study, managed and analyzed data, and drafted
348 the manuscript.

349 **Consent for publication**

350 Participants' consents for publication are not required for this data analysis project.

351 **Data Availability**

352 It is against the policy of Statistics Act of Canada to release the CHMS data. The
353 collection of CHMS data has been approved by the ethics committee within the governments of
354 Canada. The CHMS data have been de-identified and maintained by Statistics Canada. The data
355 can be accessed through the Research Data Centres administered by Statistics Canada. The
356 details and eligibility for obtaining data access can be found online at
357 <https://www.statcan.gc.ca/eng/rdc/process>.

358

359 References

- 360 1. Institute for Health Metrics and Evaluation. Canada. Seattle, WA: University of
361 Washington; 2019. Available from: <http://www.healthdata.org/canada>.
- 362 2. Diana Sherifali R, Robyn L. Diabetes Canada clinical practice guidelines expert committee.
363 Can J Diabet. 2018;42:S6-S9.
- 364 3. Roehrig C, Daly M. Prevalence Trends For Three Common Medical Conditions: Treated
365 And Untreated. Health Affairs. 2015;34(8):1320-3. doi: 10.1377/hlthaff.2015.0283.
- 366 4. Rosella LC, Lebenbaum M, Fitzpatrick T, Zuk A, Booth GL. Prevalence of prediabetes and
367 undiagnosed diabetes in Canada (2007–2011) according to fasting plasma glucose and HbA1c
368 screening criteria. Diabetes care. 2015;38(7):1299-305.
- 369 5. Roep BO. The role of T-cells in the pathogenesis of Type 1 diabetes: from cause to cure.
370 Diabetologia. 2003;46(3):305-21.
- 371 6. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Medical clinics. 2004;88(4):787-
372 835.
- 373 7. Government of Canada. Type 2 diabetes. Ottawa, ON: Government of Canada; 2019.
374 Available from: [https://www.canada.ca/en/public-health/services/diseases/type-2-](https://www.canada.ca/en/public-health/services/diseases/type-2-diabetes.html)
375 [diabetes.html](https://www.canada.ca/en/public-health/services/diseases/type-2-diabetes.html).
- 376 8. American Diabetes Association. 2. Classification and Diagnosis of Diabetes. Diabetes
377 Care. 2015;38(Supplement 1):S8.
- 378 9. Association AD. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2012;35
379 Suppl 1:S64-71. Epub 2012/01/04. doi: 35/Supplement_1/S64 [pii]
380 10.2337/dc12-s064 [doi]. PubMed Central PMCID: PMC3632174.
- 381 10. MacPherson M, de Groh M, Loukine L, Prud'homme D, Dubois L. Prevalence of
382 metabolic syndrome and its risk factors in Canadian children and adolescents: Canadian Health
383 Measures Survey Cycle 1 (2007-2009) and Cycle 2 (2009-2011). Health promotion and chronic
384 disease prevention in Canada : research, policy and practice. 2016;36(2):32-40. doi:
385 10.24095/hpcdp.36.2.03. PubMed PMID: 26878492.
- 386 11. McAlister FA, Wilkins K, Joffres M, Leenen FH, Fodor G, Gee M, et al. Changes in the
387 rates of awareness, treatment and control of hypertension in Canada over the past two
388 decades. Cmaj. 2011;183(9):1007-13. Epub 2011/05/18. doi: 10.1503/cmaj.101767. PubMed
389 Central PMCID: PMC3114892.
- 390 12. Tremblay MS, Connor Gorber S. Canadian health measures survey: brief overview. Can J
391 Public Health. 2007;98(6):453-6. Epub 2008/12/02.
- 392 13. Giroux S. Canadian Health Measures Survey: sampling strategy overview. Health reports
393 / Statistics Canada, Canadian Centre for Health Information = Rapports sur la sante / Statistique
394 Canada, Centre canadien d'information sur la sante. 2007;18 Suppl:31-6.
- 395 14. Chao Y-S, Wu C-J, Wu H-C, Chen W-C. Trend analysis for national surveys: Application to
396 all variables from the Canadian Health Measures Survey cycle 1 to 4. PLOS ONE.
397 2018;13(8):e0200127. doi: 10.1371/journal.pone.0200127.
- 398 15. Chao Y-S, Wu C-J, Wu H-C, Chen W-C. Drug trends among non-institutionalized
399 Canadians and the impact of data collection changes in the Canadian Health Measures Survey
400 2007 to 2015. PloS one. 2019;14(4):e0214718-e. doi: 10.1371/journal.pone.0214718. PubMed
401 PMID: 30978234.

- 402 16. Chao Y-S, Wu C-J, Wu H-C, Hsu H-T, Tsao L-C, Cheng Y-P, et al. Opportunities and
403 challenges from leading trends in a biomonitoring project: Canadian Health Measures Survey
404 2007 to 2017. *Frontiers in Public Health*. 2020;8:460.
- 405 17. Haines DA, Saravanabhavan G, Werry K, Khoury C. An overview of human biomonitoring
406 of environmental chemicals in the Canadian Health Measures Survey: 2007–2019. *International*
407 *Journal of Hygiene and Environmental Health*. 2017;220(2, Part A):13-28. doi:
408 <https://doi.org/10.1016/j.ijheh.2016.08.002>.
- 409 18. Day B, Langlois R, Tremblay M, Knoppers BM. Canadian Health Measures Survey: ethical,
410 legal and social issues. *Health Rep*. 2007;18 Suppl:37-51. Epub 2008/01/24.
- 411 19. Statistics Canada. Canadian Health Measures Survey (CHMS) Content summary for
412 cycles 1 to 8 In: Statistics Canada, editor. Ottawa, ON: Statistics Canada,; 2015.
- 413 20. Goldenberg R, Punthakee Z. Definition, classification and diagnosis of diabetes,
414 prediabetes and metabolic syndrome. *Canadian journal of diabetes*. 2013;37:S8-S11.
- 415 21. Royal College of Physicians and Surgeons of Canada. Clinical laboratory tests - Reference
416 values. In: values Clt-R, editor. 10-2015 ed. Ottawa, ON: Royal College of Physicians and
417 Surgeons of Canada,.
- 418 22. Longo D, Fauci A, Kasper D, Hauser S, Jameson J, Loscalzo J. *Harrison's Principles of*
419 *Internal Medicine*, 19th Edition: McGraw-Hill Education; 2015.
- 420 23. Lipscombe L, Booth G, Butalia S, Dasgupta K, Eurich DT, Goldenberg R, et al.
421 Pharmacologic glycemc management of type 2 diabetes in adults. *Canadian journal of diabetes*.
422 2018;42:S88-S103.
- 423 24. Committee to Review the Department of the Interior's Biomonitoring of Environmental
424 Status and Trends Program, Board on Environmental Studies and Toxicology. *A Review of the*
425 *Biomonitoring of Environmental Status and Trends Program: The Draft Detailed Plan*.
426 Committee to Review the Department of the Interior's Biomonitoring of Environmental Status
427 and Trends Program, editor. Washington, D.C.: National Academy Press; 1995.
- 428 25. World Health Organization. *Anatomical Therapeutic Chemical (ATC) Classification*
429 *System*. 2013. 2013.
- 430 26. Padwal RS, Bienek A, McAlister FA, Campbell NRC. Epidemiology of Hypertension in
431 Canada: An Update. *Canadian Journal of Cardiology*. 2016;32(5):687-94. doi:
432 <http://dx.doi.org/10.1016/j.cjca.2015.07.734>.
- 433 27. Joffres M, Shields M, Tremblay MS, Connor Gorber S. Dyslipidemia prevalence,
434 treatment, control, and awareness in the Canadian Health Measures Survey. *Can J Public Health*.
435 2013;104(3):e252-7. Epub 2013/07/05.
- 436 28. Cutler JA, Sorlie PD, Wolz M, Thom T, Fields LE, Roccella EJ. Trends in hypertension
437 prevalence, awareness, treatment, and control rates in United States adults between 1988–
438 1994 and 1999–2004. *Hypertension*. 2008;52(5):818-27.
- 439 29. Chao YS, Boivin A, Marcoux I, Garnon G, Mays N, Lehoux P, et al. International changes
440 in end-of-life practices over time: a systematic review. *BMC Health Serv Res*. 2016;16(1):539.
441 Epub 2016/10/08. doi: 10.1186/s12913-016-1749-z. PubMed Central PMCID: PMC5048435.
- 442 30. R Development Core Team. *R: A language and environment for statistical computing*.
443 Vienna, Austria: R Foundation for Statistical Computing; 2016.
- 444 31. RStudio Team. *RStudio: Integrated Development for R*. Boston, MA: RStudio, Inc.; 2016.

- 445 32. Braga MFB, Casanova A, Teoh H, Dawson KG, Gerstein HC, Fitchett DH, et al. Treatment
446 gaps in the management of cardiovascular risk factors in patients with type 2 diabetes in
447 Canada. *Canadian Journal of Cardiology*. 2010;26(6):297-302. doi:
448 [https://doi.org/10.1016/S0828-282X\(10\)70393-7](https://doi.org/10.1016/S0828-282X(10)70393-7).
- 449 33. Hernandez-Romieu AC, Garg S, Rosenberg ES, Thompson-Paul AM, Skarbinski J. Is
450 diabetes prevalence higher among HIV-infected individuals compared with the general
451 population? Evidence from MMP and NHANES 2009–2010. *BMJ Open Diabetes Research*
452 *& Care*. 2017;5(1):e000304. doi: 10.1136/bmjdr-2016-000304.
- 453 34. Caro JJ, Getsios D, Caro I, Klittich WS, O'Brien JA. Economic evaluation of therapeutic
454 interventions to prevent type 2 diabetes in Canada. *Diabetic medicine*. 2004;21(11):1229-36.
- 455 35. Marchand-Sénécal X, Kozak R, Mubareka S, Salt N, Gubbay JB, Eshaghi A, et al. Diagnosis
456 and Management of First Case of COVID-19 in Canada: Lessons applied from SARS. *Clinical*
457 *Infectious Diseases*. 2020.
- 458 36. Bloomgarden ZT. Diabetes and COVID-19. *Journal of Diabetes*. 2020;12(4):347-8.
- 459 37. Hoerger TJ, Harris R, Hicks KA, Donahue K, Sorensen S, Engelgau M. Screening for type 2
460 diabetes mellitus: a cost-effectiveness analysis. *Annals of Internal Medicine*. 2004;140(9):689-
461 99.
462

463 **Table 1. Trends in blood insulin (pmol/l) levels and treatment statuses**

DETAIL	CYCLE 1	CYCLE 2	CYCLE 3	CYCLE 4
RATIOS AND 95% CIS(CYCLE 1 OR FIRST CYCLE = 1)	1 (1 to 1)	1 (0.75 to 1.25)	1.25 (0.95 to 1.55)	1.42 (1.04 to 1.79)
WEIGHTED MEAN	67.78 (61.14 to 74.41)	69.19 (61.27 to 77.12)	81.32 (75.87 to 86.78)	89.87 (79.61 to 100.12)
PROPORTIONS WITH VALUES LOWER THAN DETECTION LEVELS (%)		8.08	0.07	0
PROPORTIONS WITH VALUES HIGHER THAN DETECTION LEVELS (%)		0	0	0
CLINICALLY HIGH (%)		7.52	6.81	8.42
	Untreated among clinically high (%)		Insufficient sample sizes	
	Untreated (%)			
	Treated among clinically high (%)			
	Treated (%)			
	Probably treated among clinically high (%)			
	Probably treated (%)			
	Potentially treated among clinically high (%)			
	Potentially treated (%)			
CLINICALLY LOW (%)		4.49		
	Untreated among clinically low (%)	3.15 (-1.02 to 7.32)		Insufficient sample sizes
	Untreated (%)	0.14 (-0.05 to 0.33)		
	Treated among clinically low (%)	Insufficient sample sizes		
	Treated (%)			
	Probably treated among clinically low (%)	88.87 (82.32 to 95.42)		
	Probably treated (%)	3.99 (3.7 to 4.28)		
	Potentially treated among clinically low (%)	96.85 (92.68 to 101.02)		
	Potentially treated (%)	4.35 (4.15 to 4.55)		

464 CI = confidence interval. Insufficient sample sizes = insufficient unweighted sample sizes for
 465 Statistics Canada to release the weighted statistics so to protect participants' confidentiality.

466
 467
 468
 469

470 **Table 2. Trends in glycosylated hemoglobin percentages and treatment status**

DETAIL	CYCLE 1	CYCLE 2	CYCLE 3	CYCLE 4
RATIOS AND 95% CIS (CYCLE 1 OR FIRST CYCLE = 1)	1 (1 to 1)	1.07 (0.87 to 1.28)	1.01 (0.81 to 1.21)	1.02 (0.83 to 1.21)
WEIGHTED MEAN	5.58% (5.47% to 5.69%)	5.69% (5.56% to 5.82%)	5.41% (5.56% to 5.82%)	5.42% (5.36% to 5.49%)
PROPORTIONS WITH VALUES LOWER THAN DETECTION LEVELS (%)	0	0	0	0
PROPORTIONS WITH VALUES HIGHER THAN DETECTION LEVELS (%)	0	0	0	0
CLINICALLY HIGH (%)	34.12	42.17	15.88	18.83
Untreated among clinically high (%)	3.86 (2.1 to 5.62)	3.75 (2.5 to 5)	1.78 (0.19 to 3.67)	3.73 (-0.37 to 7.83)
Untreated (%)	1.32 (0.71 to 1.93)	1.58 (1.05 to 2.11)	0.28 (0.03 to 0.58)	0.7 (-0.06 to 1.46)
Treated among clinically high (%)	11.38 (7.52 to 15.24)	12.89 (9.24 to 16.54)	29.91 (22.38 to 37.44)	25.37 (19.94 to 30.8)
Treated (%)	3.88 (2.57 to 5.19)	5.44 (3.89 to 6.99)	4.75 (3.55 to 5.95)	4.78 (3.76 to 5.8)
Probably treated among clinically high (%)	87.47 (84.28 to 90.66)	87.21 (84.27 to 90.15)	92.28 (87.38 to 97.18)	93.22 (90.28 to 96.16)
Probably treated (%)	29.84 (28.74 to 30.94)	36.78 (35.55 to 38.01)	14.65 (13.87 to 15.43)	17.55 (17 to 18.1)
Potentially treated among clinically high (%)	96.14 (94.38 to 97.9)	96.25 (95 to 97.5)	98.22 (96.63 to 99.81)	96.27 (92.17 to 100.37)
Potentially treated (%)	32.8 (32.19 to 33.41)	40.59 (40.06 to 41.12)	15.6 (15.35 to 15.85)	18.13 (17.37 to 18.89)
CLINICALLY LOW (%)	Insufficient sample sizes			
Untreated among clinically low (%)				
Untreated (%)				
Treated among clinically low (%)				
Treated (%)				
Probably treated among clinically low (%)				
Probably treated (%)				
Potentially treated (%)				

	treated among clinically low (%)	
	Potentially treated (%)	

471 CI = confidence interval; Insufficient sample sizes = insufficient unweighted sample sizes for
472 Statistics Canada to release the weighted statistics so to protect participants' confidentiality. No
473 subjects with glycosylated hemoglobin percentages lower than the lower bound of the clinical
474 reference range.

475
476
477
478
479

480 **Table 3. Trends in blood random-spot glucose levels (mmol/l) and treatment status**

	CYCLE 1	CYCLE 2	CYCLE 3	CYCLE 4
RATIOS AND 95% CIS (CYCLE 1 OR FIRST CYCLE = 1)				
WEIGHTED MEAN	1 (1 to 1)	1.09 (0.9 to 1.27)		
	4.96 (4.93 to 5)	5.08 (4.99 to 5.16)		
PROPORTIONS WITH VALUES LOWER THAN DETECTION LEVELS (%)		0		0
PROPORTIONS WITH VALUES HIGHER THAN DETECTION LEVELS (%)		0		0
CLINICALLY HIGH (%)		0.75		0.84
Untreated among clinically high (%)	0	0		
Untreated (%)	0	0		
Treated among clinically high (%)	78.84 (71.24 to 86.44)	93.02 (84.55 to 101.49)		
Treated (%)	0.59 (0.53 to 0.65)	0.78 (0.7 to 0.86)		
Probably treated among clinically high (%)	100 (100 to 100)	100 (100 to 100)		
Probably treated (%)	0.75 (0.75 to 0.75)	0.84 (0.84 to 0.84)		
Potentially treated among clinically high (%)	100 (100 to 100)	100 (100 to 100)		
Potentially treated (%)	0.75 (0.75 to 0.75)	0.84 (0.84 to 0.84)		
CLINICALLY LOW (%)				
Untreated among clinically low (%)				
Untreated (%)				
Treated among clinically low (%)				
Treated (%)				
Probably treated among clinically low (%)				
Probably treated (%)				
Potentially treated among clinically low (%)				
Potentially treated (%)				

Not measured

Insufficient sample sizes

481 CI = confidence interval; Insufficient sample sizes: insufficient unweighted sample sizes for
 482 Statistics Canada to release the weighted statistics so to protect participants' confidentiality.
 483
 484

485 **Table 4. Trends in blood fasting glucose levels (mmol/l) and treatment status**

RATIOS AND 95% CIS (CYCLE 1 OR FIRST CYCLE = 1)		CYCLE 1	CYCLE 2	CYCLE 3	CYCLE 4
				1 (1 to 1)	1.03 (0.91 to 1.16)
WEIGHTED MEAN				5.17 (5.05 to 5.28)	5.2 (5.14 to 5.27)
PROPORTIONS WITH VALUES LOWER THAN DETECTION LEVELS (%)				0	0
PROPORTIONS WITH VALUES HIGHER THAN DETECTION LEVELS (%)				0	0
CLINICALLY HIGH (%)				14.42	14.38
	Untreated among clinically high (%)			0.44 (0 to 1.05)	0.72 (0.17 to 1.27)
	Untreated (%)			0.07 (0 to 0.15)	0.1 (0.02 to 0.18)
	Treated among clinically high (%)			27 (18.4 to 35.6)	32.2 (21.69 to 42.71)
	Treated (%)			3.89 (2.66 to 5.12)	4.63 (3.12 to 6.14)
	Probably treated among clinically high (%)			93.37 (86.41 to 100.33)	96 (93.3 to 98.7)
	Probably treated (%)			13.46 (12.46 to 14.46)	13.8 (13.41 to 14.19)
	Potentially treated among clinically high (%)			99.54 (98.95 to 100)	99.28 (98.73 to 99.83)
	Potentially treated (%)			14.35 (14.27 to 14.43)	14.28 (14.2 to 14.36)
CLINICALLY LOW (%)				1.92	0.53
	Untreated among clinically low (%)			5.23 (1.09 to 9.37)	3.26 (0 to 7.47)
	Untreated (%)			0.1 (0.02 to 0.18)	0.02 (0 to 0.04)
	Treated among clinically low (%)			Insufficient sample sizes	
	Treated (%)			59.84 (24.66 to 95.02)	72.36 (52.43 to 92.29)
	Probably treated among clinically low (%)			1.15 (0.48 to 1.82)	0.38 (0.28 to 0.48)
	Probably treated (%)			94.77 (90.63 to 98.91)	96.74 (92.53 to 100)
	Potentially treated among clinically low (%)			1.82 (1.74 to 1.9)	0.51 (0.49 to 0.53)
	Potentially treated (%)				

Not measured

486 CI = confidence interval; Insufficient sample sizes: insufficient unweighted sample sizes for
 487 Statistics Canada to release the weighted statistics so to protect participants' confidentiality.
 488
 489
 490
 491